You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company said it now has payor coverage for more than 130 million individuals.
The company obtained out-of-state provider status from California's Medicaid program for its OVA1 test, giving it access to more than 12 million patients.
The G-BA commissioned a contractor to prepare an evidence report by early 2018 and to gather information for patients by early 2019.
The firm said it is now an in-network provider with the country's fourth-largest health insurer.
The firm said that the new coverage for its Afirma thyroid cancer test makes it a medically necessary benefit for nearly 24 million Blues plan members.
Starting Feb. 15, Aetna members will be able to access NxGen MDx's genetic screening and noninvasive prenatal testing as an in-network benefit.
The coverage decision provides Humana's 13 million members with access to the test, which provides a numerical score to assess the risk of disease recurrence.
Members of the health plan will have access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.
With a recent draft guidance from Medicare contractor Palmetto, and $6.1 million in new funding, Indi hopes to launch the test in the next six to nine months.
EndoPredict is a kit-based RNA expression test that evaluates 12 genes to assess the aggressiveness of breast cancer on a molecular level, and is set to launch in the US this year.